CCS1477 + abiraterone acetate

CCS1477 + abiraterone acetate is a **combination therapy** under clinical investigation for the treatment of advanced prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). **CCS1477** is an oral small molecule inhibitor that targets the bromodomain proteins p300 and CBP, which act as key epigenetic regulators of cancer gene transcription. By binding to p300 and CBP, CCS1477 downregulates androgen receptor (AR) expression, including AR mutations and splice variants (AR-SV), and also affects other oncogenic drivers such as c-Myc. **Abiraterone acetate** is an androgen biosynthesis inhibitor, acting by irreversibly inhibiting the enzyme CYP17A1, thereby blocking androgen production within the testes, adrenal glands, and prostate tumor tissue. This dual approach aims to suppress both the source and the downstream signaling of androgens, potentially overcoming resistance to anti-androgen therapies.

Brand names

Yonsa

Other names

abiraterone acetateabiraterone